15.01.2024 • NewsWuxiWuXi Biologicsinvestment

WuXi Biologics Expands Production Capacity at Massachusetts Site

China-headquartered contract research, development and manufacturing organization (CRDMO) WuXi Biologics plans to increase the manufacturing capacity of its US facility in Worcester, Massachusetts to 36,000 l, 12,000 l more than the originally planned 24,000 l.

Construction of the new 189,500-square-foot facility is underway and WuXi expects the site to be operational in 2025 with GMP release in 2026.

According to WuXi, the expansion of the facility will add another 200 employees to the current 400 in the USA.

Chris Chen, CEO of WuXi Biologics, said: “The new commercial capacity in Worcester, Massachusetts represents a key part of our global biomanufacturing network, reflecting our commitment to continuously strengthen our capabilities in line with anticipated market and client needs.”

Last year, WuXi Biologics launched its first Boston Research Service Center, the company’s fourth site in the US after its clinical manufacturing facility in New Jersey and process development and characterization laboratories in Pennsylvania.

© WuXi Biologics
© WuXi Biologics

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.